COMMENTARY

Corticotropin releasing factor

Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?

Y Taché

Correspondence to:
Correspondence to:
Dr Y Taché
CURE/Digestive Diseases Research Center, Bldg 115, Room 117, VA Greater Los Angeles Health Care System, 1130 Wilshire Blvd, Los Angeles, CA 90073, USA; yTaché@ucla.edu

---

New corticotropin releasing factor (CRF) antagonists in irritable bowel disease (IBS) warrant testing, and CRF₁ receptors may be a promising target for the treatment of IBS

---

Keywords: corticotropin releasing factor; corticotropin releasing factor receptor; colonic motility; inflammation; irritable bowel syndrome

The first 150 words of the full text of this article appear below.

Recent years have witnessed important developments in the understanding of the biochemical coding of stress.¹ In addition to the 41 amino acid peptide, corticotropin releasing factor (CRF), novel mammalian CRF related peptides, urocortin 1, urocortin 2, and urocortin 3 have recently been discovered.² These CRF ligands display distinct affinity to the two cloned G protein coupled CRF 1 (CRF₁) and 2 (CRF₂) receptors.^1–3 CRF has higher affinity for CRF₁ than for CRF₂ receptor, urocortin 1 displays equal affinity for both subtypes, and urocortin 2 and 3 have selective affinity for CRF₂ receptor.^2,3 In addition to the mapping of CRF ligands and receptors in the brain^2,4 and gut,^5–7 the development of potent selective CRF₁ and CRF₂ antagonists^8,9 and generation of transgenic mouse models¹ provided tremendous insight in the investigation of the underlying mechanisms of stress. Convergent studies established the role of the brain CRF-CRF₁ pathways in . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome

Y Sagami, Y Shimada, J Tayama, T Nomura, M Satake, Y Endo, T Shoji, K Karahashi, M Hongo, and S Fukudo
Gut 2004 53: 958-964. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Wald, A., Rakel, D. (2008). Behavioral and Complementary Approaches for the Treatment of Irritable Bowel Syndrome. Nutr Clin Pract 23: 284-292 [Abstract] [Full Text]  
• Fukudo, S, Saito, K, Sagami, Y, Kanazawa, M (2006). Can modulating corticotropin releasing hormone receptors alter visceral sensitivity?. Gut 55: 146-148 [Full Text]  
• Million, M, Wang, L, Wang, Y, Adelson, D W, Yuan, P-Q, Maillot, C, Coutinho, S V, Mcroberts, J A, Bayati, A, Mattsson, H, Wu, V, Wei, J-Y, Rivier, J, Vale, W, Mayer, E A, Tache, Y (2006). CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats. Gut 55: 172-181 [Abstract] [Full Text]